Medicine
Glycemic Control Targets and Insulin Therapy in Hospitalized Patients
Quick fact
Stress hyperglycemia in hospitalized patients is associated with worse outcomes, but aggressive glucose lowering to normal levels can increase mortality—the right target is a delicate balance.
Why this is interesting
You've just been admitted to the hospital for pneumonia, and your blood sugar is 220 mg/dL—but you've never had diabetes. Should the doctors treat it? Their decision could affect how quickly you recover.
Read the full explanation
Understanding Glycemic Control Targets and Insulin Therapy in Hospitalized Patients
When you're in the hospital, your body may release stress hormones like cortisol and adrenaline, which raise blood glucose. Even if you've never had diabetes, this 'stress hyperglycemia' is common and can lead to complications like poor wound healing or infections. To manage it, doctors aim for glucose levels that are neither too high nor too low. In non-critical care settings, the typical target is a pre-meal glucose below 140 mg/dL with random levels below 180 mg/dL. In critical care (like the ICU), the target is often tighter, around 140–180 mg/dL. Achieving these targets usually requires insulin, because oral diabetes medications may be unsafe or less effective during acute illness. Insulin is given in a 'basal-bolus' pattern: a long-acting insulin once daily to cover baseline needs, and rapid-acting insulin before meals to cover the rise in glucose from eating. This mimics how the body normally releases insulin, and is safer than the older 'sliding-scale' alone, which just reacts to high glucose after it occurs.
A deeper explanation
The rationale for these targets comes from research showing both hyperglycemia and hypoglycemia are harmful. High glucose can impair immune function and cause osmotic diuresis, leading to dehydration; low glucose can cause neurological damage. Landmark trials like NICE-SUGAR found that intensive insulin therapy targeting normal glucose (80–110 mg/dL) increased mortality, mainly due to severe hypoglycemia. Therefore, guidelines recommend a moderate target of 140–180 mg/dL in critically ill patients. For non-critically ill patients, targets are slightly lower to prevent symptoms and long-term risks. Insulin is preferred because it can be titrated precisely: intravenous infusions allow rapid adjustment in unstable patients, while subcutaneous basal-bolus regimens provide stable coverage. Sliding-scale insulin alone fails to prevent hyperglycemia because it only reacts after the fact. In practice, clinicians must monitor glucose frequently, adjust infusions based on trends, and be vigilant for hypoglycemia, especially in patients with renal impairment or reduced oral intake. This concept matters because optimal glucose control reduces morbidity, shortens hospital stays, and prevents readmissions—making it a cornerstone of inpatient medicine.